Healthcare -
Biotechnology - NASDAQ - US
$ 0.3619
-0.304 %
$ 8.37 M
Market Cap
-0.13
P/E
1. INTRINSIC VALUE
Balance Sheet
Turnstone Biologics Corp.
| Current Assets | 34.2 M |
| Cash & Short-Term Investments | 28.9 M |
| Receivables | 0 |
| Other Current Assets | 5.29 M |
| Non-Current Assets | 5.92 M |
| Long-Term Investments | 0 |
| PP&E | 5.11 M |
| Other Non-Current Assets | 811 K |
| Current Liabilities | 8.2 M |
| Accounts Payable | 870 K |
| Short-Term Debt | 1.08 M |
| Other Current Liabilities | 6.24 M |
| Non-Current Liabilities | 473 K |
| Long-Term Debt | 104 K |
| Other Non-Current Liabilities | 369 K |
EFFICIENCY
Earnings Waterfall
Turnstone Biologics Corp.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 72.5 M |
| Operating Income | -72.5 M |
| Other Expenses | -1.66 M |
| Net Income | -70.8 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Turnstone Biologics Corp.
| Net Income | -70.8 M |
| Depreciation & Amortization | 1.84 M |
| Capital Expenditures | -229 K |
| Stock-Based Compensation | 3.68 M |
| Change in Working Capital | 47 K |
| Others | -3.14 M |
| Free Cash Flow | -67.7 M |
Wall Street Analysts Price Targets
Turnstone Biologics Corp.
Wall Street analysts predict an average 1-year price target for TSBX of $0.5 , with forecasts ranging from
a
low of
$0.5 to a high of $0.5 .
TSBX Lowest Price Target
Wall Street Target
0.5 USD
38.16%
TSBX Average Price Target
Wall Street Target
0.5 USD
38.16%
TSBX Highest Price Target
Wall Street Target
0.5 USD
38.16%
4. DIVIDEND
ANALYSIS
TSBX does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Turnstone Biologics Corp.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Turnstone Biologics Corp. (NASDAQ: TSBX)
NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Turnstone Biologics Corp. (NASDAQ: TSBX ) related to its sale to XOMA Royalty Corporation in which existing Turnstone shareholders will receive $0.34 in cash per share and one non-transferable contingent value right. Is it a fair deal?
globenewswire.com
- 3 weeks ago
TSBX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Turnstone Biologics Corp. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Turnstone Biologics Corp. (NASDAQ: TSBX) to XOMA Royalty Corporation for $0.34 in cash per share plus one non-transferable contingent value right is fair to Turnstone shareholders. Halper Sadeh encourages Turnstone shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper.
businesswire.com
- 4 weeks ago
Turnstone Biologics Corp. Reports First Quarter 2025 Financial Results and Provides Recent Corporate Highlights
SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq-CM: TSBX), a biotechnology company historically focused on the development of a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (“Selected TIL”) therapy, today reported financial results for the first quarter ended March 31, 2025, and provided recent corporate updates. Corporate Updates In January 2025, Turnstone made the determination to discontinue all TIDAL-01 clinical studies and halted further development of the program.
globenewswire.com
- 2 months ago
Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results
SAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a biotechnology company historically focused on the development of a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (“Selected TIL”) therapy, today announced its financial results for the fourth quarter and full year ended December 31, 2024, and provided recent corporate updates. Corporate Updates In November 2024, the Company presented preclinical data on its Selected TIL therapies at the 2024 Society for Immunotherapy of Cancer (“SITC”) Annual Meeting.
globenewswire.com
- 3 months ago
Turnstone Biologics Corp. (TSBX) Upgraded to Buy: What Does It Mean for the Stock?
Turnstone Biologics Corp. (TSBX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.com
- 5 months ago
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Turnstone's next-generation Selected TIL technology is designed to selectively expand the most potent tumor-reactive T cells for treatment of solid tumors Results further support the continued clinical advancement of TIDAL-01, currently being evaluated in Phase 1 trials SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced it will be presenting two posters highlighting preclinical data on methods for TIL selection at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting being held November 6-10, 2024 in Houston, Texas. “We remain confident that delivering a TIL-based product with a higher proportion of tumor-reactive T cells is the key to extending the clinical application of TILs across a broader range of solid tumors,” said David Stojdl, Ph.D.
globenewswire.com
- 8 months ago
Turnstone Biologics Shifts Focus To 'High Unmet Medical Need' Cancers, Shares Initial Data From Colorectal Cancer Cell Therapy Study
Turnstone Biologics Corp. TSBX stock is trading lower after the company released initial data from its Phase 1 STARLING trial of TIDAL-01 in metastatic microsatellite-stable colorectal cancer (MSS mCRC) on Thursday.
benzinga.com
- 11 months ago
Why Is Turnstone Biologics (TSBX) Stock Down 38% Today?
Turnstone Biologics (NASDAQ: TSBX ) stock is falling on Thursday following the release of the clinical-stage biotechnology company's earnings report. The bad news pulling TSBX stock down today is the company's diluted earnings per share of -92 cents.
investorplace.com
- 11 months ago
Turnstone Biologics Corp. Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights
Announced positive initial data from Phase 1 trial of TIDAL-01 in metastatic colorectal cancer including a complete response in one of the four patients reported Cash position expected to fund operations into 3Q 2025 SAN DIEGO, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported financial results for the second quarter ended June 30, 2024, and provided recent business highlights. “We have continued to bolster our position by making advances across our pipeline and corporate operations in the second quarter of 2024.
globenewswire.com
- 11 months ago
Turnstone Biologics Corp. Reports Positive Initial Data from Phase 1 Trial of TIDAL-01 in Metastatic Colorectal Cancer
Overall response rate (“ORR”) of 25% and 50% disease control rate ("DCR") observed in first four evaluable patients treated with TIDAL-01 with advanced CRC Complete response achieved in heavily pre-treated late line patient with progression free survival extending beyond one year Favorable tolerability profile and demonstrated manufacturing success Product characterization and translational data support biological hypothesis for Selected TILs SAN DIEGO, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported positive initial data from its Phase 1 STARLING trial of TIDAL-01 in metastatic microsatellite stable colorectal cancer (“MSS mCRC”). Turnstone's Phase 1 STARLING trial is an ongoing muti-site, first-in-human, non-randomized, open label, single-dose study, and is evaluating the safety, tolerability, and clinical activity of TIDAL-01.
globenewswire.com
- 11 months ago
4 Stocks Under $5 To Buy Now
Are you looking for stocks to buy with low price tags?
247wallst.com
- 11 months ago
Turnstone Biologics Corp. Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights
SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported financial results for the first quarter ended March 31, 2024, and provided recent business highlights. “We are excited about the therapeutic potential of our pipeline of next-generation Selected TIL therapies,” said Sammy Farah, M.B.A.
globenewswire.com
- 1 year ago
8. Profile
Summary
Turnstone Biologics Corp. TSBX
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 8.37 M
Dividend Yield
0.00%
Description
Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, and uveal melanoma, as well as an investigator sponsored trial to treat cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.
Contact
9310 Athena Circle, LA Jolla, CA, 92037
https://turnstonebio.com
IPO
Date
July 21, 2023
Employees
14
Officers
Dr. Sammy J. Farah M.B.A., Ph.D.
President, Chief Executive Officer & Director
Dr. Michael Fitch Ph.D.
Senior Vice President of Manufacturing
Ms. Saryah Azmat
Chief Operating Officer & Corporate Secretary
Dr. Ines Verdon M.D.
Senior Vice President of Clinical Development
Ms. Wendy Worcester CFA, CPA
Vice President, Principal Finance & Accounting Officer
Dr. David Stojdl Ph.D.
Senior Vice President of Research & Discovery